At the time of writing, Aclaris Therapeutics Inc [ACRS] stock is trading at $1.55, saw in change for the day. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ACRS shares have gain 1.31% over the last week, with a monthly amount glided 6.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wedbush started tracking the stock with Outperform rating on May 28, 2025, and set its price target to $8. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $20 on December 23, 2024. Cantor Fitzgerald upgraded its rating to a Overweight. Leerink Partners upgraded its rating to Outperform for this stock on November 19, 2024, and upped its price target to $7. In a note dated November 19, 2024, Jefferies upgraded an Buy rating on this stock and boosted its target price from $2 to $7.
For the past year, the stock price of Aclaris Therapeutics Inc fluctuated between $1.05 and $5.17. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Aclaris Therapeutics Inc [NASDAQ: ACRS] shares were valued at $1.55 at the most recent close of the market. An investor can expect a potential return of 593.55% based on the average ACRS price forecast.
Analyzing the ACRS fundamentals
According to Aclaris Therapeutics Inc [NASDAQ:ACRS], the company’s sales were 17.78M for trailing twelve months, which represents an -39.32% plunge. Gross Profit Margin for this corporation currently stands at 0.21% with Operating Profit Margin at -7.92%, Pretax Profit Margin comes in at -7.32%, and Net Profit Margin reading is -7.32%. To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is -0.92 and Total Capital is -0.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Aclaris Therapeutics Inc [NASDAQ:ACRS] has a current ratio of 5.06. As well, the Quick Ratio is 5.06, while the Cash Ratio is 1.41. Considering the valuation of this stock, the price to sales ratio is 9.44, the price to book ratio is 1.16.
Transactions by insiders
Recent insider trading involved Mehra Anand, Director, that happened on Nov 19 ’24 when 0.67 million shares were purchased.
